NO20052223L - Tiazolforbindelser for behandling av neurodegenerative forstyrrelser - Google Patents

Tiazolforbindelser for behandling av neurodegenerative forstyrrelser

Info

Publication number
NO20052223L
NO20052223L NO20052223A NO20052223A NO20052223L NO 20052223 L NO20052223 L NO 20052223L NO 20052223 A NO20052223 A NO 20052223A NO 20052223 A NO20052223 A NO 20052223A NO 20052223 L NO20052223 L NO 20052223L
Authority
NO
Norway
Prior art keywords
treatment
neurodegenerative disorders
thiazole compounds
compounds
formula
Prior art date
Application number
NO20052223A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052223D0 (no
Inventor
Yuhpyng Liang Chen
Michael Leon Corinan
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20052223D0 publication Critical patent/NO20052223D0/no
Publication of NO20052223L publication Critical patent/NO20052223L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38Nitrogen atoms
    • C07D277/44Acylated amino or imino radicals
    • C07D277/46Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/54Nitrogen and either oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62Benzothiazoles
    • C07D277/68Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20052223A 2002-10-09 2005-05-06 Tiazolforbindelser for behandling av neurodegenerative forstyrrelser NO20052223L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41740002P 2002-10-09 2002-10-09
US46320903A 2003-06-17 2003-06-17
PCT/IB2003/004330 WO2004033439A1 (en) 2002-10-09 2003-09-29 Thiazole compounds for the treatment of neurodegenerative disorders

Publications (2)

Publication Number Publication Date
NO20052223D0 NO20052223D0 (no) 2005-05-06
NO20052223L true NO20052223L (no) 2005-07-04

Family

ID=35306299

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052223A NO20052223L (no) 2002-10-09 2005-05-06 Tiazolforbindelser for behandling av neurodegenerative forstyrrelser

Country Status (28)

Country Link
US (1) US20040152747A1 (nl)
EP (1) EP1551815A1 (nl)
JP (1) JP2006504796A (nl)
KR (1) KR20050070046A (nl)
CN (1) CN1688557A (nl)
AP (1) AP2005003274A0 (nl)
AR (1) AR043051A1 (nl)
AU (1) AU2003265068A1 (nl)
BR (1) BR0314611A (nl)
CA (1) CA2501803A1 (nl)
CO (1) CO5550435A2 (nl)
CR (1) CR7785A (nl)
EC (1) ECSP055719A (nl)
GT (1) GT200300219A (nl)
IS (1) IS7738A (nl)
MA (1) MA27451A1 (nl)
MX (1) MXPA05002420A (nl)
NL (1) NL1024499C2 (nl)
NO (1) NO20052223L (nl)
OA (1) OA12937A (nl)
PA (1) PA8585001A1 (nl)
PE (1) PE20040640A1 (nl)
PL (1) PL376171A1 (nl)
TN (1) TNSN05104A1 (nl)
TW (1) TW200420550A (nl)
UY (1) UY28011A1 (nl)
WO (1) WO2004033439A1 (nl)
ZA (1) ZA200502841B (nl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2004099200A1 (en) 2003-05-12 2004-11-18 Pfizer Products Inc. Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders
EP1653952A4 (en) * 2003-08-06 2007-04-04 Pfizer Prod Inc OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER
FR2865206B1 (fr) * 2004-01-16 2009-02-06 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
FR2873370B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
JP2007517840A (ja) 2004-01-16 2007-07-05 サノフイ−アベンテイス アシルアミノチアゾール誘導体、それらの調製方法及び治療における該誘導体の使用
FR2873374B1 (fr) * 2004-07-22 2006-10-20 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
WO2005073202A1 (fr) 2004-01-16 2005-08-11 Sanofi-Aventis Derives d’acylaminothiazole et leur application comme inhibiteurs de beta-amyloide
FR2865207B1 (fr) * 2004-01-16 2008-10-17 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique
BRPI0509069B8 (pt) * 2004-03-23 2021-05-25 Pfizer Prod Inc compostos de imidazol e composição farmacêutica que os compreende para o tratamento de distúrbios neurodegenerativos
US7384968B2 (en) 2004-04-01 2008-06-10 Pfizer Inc. Thiazole-amine compounds for the treatment of neurodegenerative disorders
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
CA2575466A1 (en) 2004-08-13 2006-02-23 Genentech, Inc. Thiazole based inhibitors of atp-utilizing enzymes
JP5203937B2 (ja) * 2005-05-24 2013-06-05 メルク セローノ ソシエテ アノニム チアゾール誘導体及びその使用
FR2887879B1 (fr) * 2005-07-01 2008-09-26 Trophos Sa Nouveaux composes chimiques et leurs utilisations comme medicament,particulierement dans le traitement des maladies neurodegeneratives
RS20080139A (en) * 2005-09-22 2009-05-06 Pfizer Products Inc., Imidazole coumpounds for the treatment of neurological disorders
CA2631750A1 (en) 2005-12-01 2007-06-07 The Scripps Research Institute Compositions and methods for inducing neuronal differentiation
US7514566B2 (en) * 2006-01-18 2009-04-07 Amgen, Inc. Thiazole compounds and methods of use
EP1918286B1 (en) * 2006-11-05 2011-12-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Thiazolhydrazides for treatment of neurodegenerative diseases
GB0701426D0 (en) * 2007-01-25 2007-03-07 Univ Sheffield Compounds and their use
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
WO2009011871A2 (en) * 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
EP2548618A3 (en) * 2008-07-15 2013-02-27 Novartis AG Heteroaryl derivatives as DGAT1 inhibitors
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
WO2010126002A1 (ja) * 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
US8299103B2 (en) * 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
CN102351854B (zh) * 2011-07-29 2014-06-04 华中科技大学 氨基噻唑衍生物及制备方法和医药用途
AU2014241065B2 (en) * 2013-03-14 2017-08-31 Merck Patent Gmbh Glycosidase inhibitors
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
CN103408541B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 吲哚取代的噻唑并环己烷类化合物、及其抗肿瘤用途
CN103435573B (zh) * 2013-07-16 2015-04-01 浙江医药高等专科学校 苄基取代的噻唑并环己烷类化合物、其制备方法和用途
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
US11274100B2 (en) 2017-06-21 2022-03-15 Daiichi Sankyo Company, Limited EP300/CREBBP inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021360A1 (en) * 1991-05-28 1992-12-10 Merck & Co., Inc. Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
CO5021134A1 (es) * 1998-05-01 2001-03-27 Abbott Lab Inhibidores beta-aminoacidos substituidos de aminopeptida- sa-2 metionina
BR9910092A (pt) * 1998-05-01 2002-01-22 Abbott Lab Inibidores de beta-aminoácido substituìdo de metionina aminopeptidase-2
WO2000024392A1 (fr) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited Inhibiteur de la formation de beta-amyloide
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
FR2842523A1 (fr) * 2002-07-17 2004-01-23 Sanofi Synthelabo Derives d'acylaminothiazole, leur preparation et leur application en therapeutique

Also Published As

Publication number Publication date
NO20052223D0 (no) 2005-05-06
BR0314611A (pt) 2005-07-26
US20040152747A1 (en) 2004-08-05
EP1551815A1 (en) 2005-07-13
GT200300219A (es) 2004-05-18
CA2501803A1 (en) 2004-04-22
NL1024499A1 (nl) 2004-04-13
PA8585001A1 (es) 2004-12-16
ZA200502841B (en) 2006-03-29
NL1024499C2 (nl) 2004-10-13
MA27451A1 (fr) 2005-07-01
KR20050070046A (ko) 2005-07-05
TNSN05104A1 (fr) 2007-05-14
MXPA05002420A (es) 2005-10-05
PL376171A1 (en) 2005-12-27
WO2004033439A1 (en) 2004-04-22
TW200420550A (en) 2004-10-16
CO5550435A2 (es) 2005-08-31
CR7785A (es) 2005-07-08
AU2003265068A1 (en) 2004-05-04
ECSP055719A (es) 2005-07-06
IS7738A (is) 2005-03-10
AR043051A1 (es) 2005-07-13
OA12937A (en) 2006-10-13
PE20040640A1 (es) 2004-09-15
UY28011A1 (es) 2004-04-30
AP2005003274A0 (en) 2005-06-30
CN1688557A (zh) 2005-10-26
JP2006504796A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20052223L (no) Tiazolforbindelser for behandling av neurodegenerative forstyrrelser
NO20064726L (no) Imidazolforbindelser for behandling av neurodegenerative forstyrrelser
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
NO20064989L (no) Sulfonamidforbindelser for behandling av neurodegenerative lidelser
NO20071719L (no) Pyridylinhibitorer for "hedgehog"-signalisering
DK2527315T3 (da) Forbindelser, præparater og fremgangsmåder til behandling af amyloide sygdomme og synukleinopatier, såsom Alzheimers sygdom, type 2-diabetes og Parkinsons sygdom
GB0318447D0 (en) Therapeutic agents
CA2473070A1 (en) Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
NO20045137L (no) Diketohydrazinderivatforbindelser og legemidler inneholdende forbindelser som aktiv ingrediens
MXPA05011150A (es) 2-hidroxi-3-diaminoalcanos de benzamida.
NO20060020L (no) 3-fluorpiperidiner som NMDA/NR2B-antagonister
MXPA04003245A (es) Hidroxipropilaminas.
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
MXPA04002785A (es) Aminas sustituidas para tratamiento de enfermedad de alzheimer.
CA2534532A1 (en) Compounds for the treatment of neurodegenerative disorders
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
MXPA03011466A (es) Macrociclos utiles en tratamiento de enfermedades de alzheimer.
ATE437855T1 (de) (4,5,6,7-tetrahydro-1h-indol-7- yl)essigsäurederivate zur behandlung von alzheimer-krankheit
MX2010002765A (es) Derivado de 6-pirimidinil-pirimid-4-ona.
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
EP1958939A3 (en) Pyrazole-amine compounds for the treatment of neurodegenerative disorders
NO20081845L (no) Imidazolforbindelser for behandling av neurologiske lidelser